Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise in early trial for advanced cancers

NCT ID NCT03564691

Completed Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested an experimental drug called MK-4830, either by itself or combined with other cancer therapies like pembrolizumab, in 470 people with advanced solid tumors. The main goals were to check safety, find the right dose, and see if tumors shrank. The study is complete, but results are not yet reported.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma head and neck squamous cell carcinoma neoplasm non-small cell lung carcinoma pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS

Contacts and locations

Locations

  • Cancercare Rondebosch Oncology ( Site 0210)

    Cape Town, Western Cape, 7700, South Africa

  • Centre Hospitalier Universitaire de Poitiers ( Site 2000)

    Poitiers, Vienne, 86000, France

  • Centre Oscar Lambret ( Site 2002)

    Lille, Nord, 59000, France

  • Centro Integral Oncologico Clara Campal START Madrid ( Site 0102)

    Madrid, 28050, Spain

  • Chaim Sheba Medical Center. ( Site 0044)

    Ramat Gan, 5265601, Israel

  • Euromedica General Clinic of Thessaloniki-Oncology Unit ( Site 0112)

    Thessaloniki, 546 45, Greece

  • European Interbalkan Medical Center ( Site 0111)

    Thessaloniki, 57001, Greece

  • Henry Ford Health System ( Site 0002)

    Detroit, Michigan, 48202, United States

  • Hôpital Européen Georges Pompidou ( Site 2003)

    Paris, Île-de-France Region, 75015, France

  • Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 0101)

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

  • Japanese Foundation for Cancer Research ( Site 0401)

    Tokyo, 135-8550, Japan

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0005)

    Hackensack, New Jersey, 07601, United States

  • Juravinski Cancer Centre ( Site 0034)

    Hamilton, Ontario, L8V 5C2, Canada

  • Laura and Isaac Perlmutter Cancer Center ( Site 0008)

    New York, New York, 10016, United States

  • Liverpool Hospital-Medical Oncology ( Site 0250)

    Liverpool, New South Wales, 2170, Australia

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • National Cancer Center Hospital East ( Site 0400)

    Kashiwa, Chiba, 2778577, Japan

  • Ohio State University Arthur G James Cancer Hospital & Richard J Solove Research Institute ( Site 00

    Columbus, Ohio, 43210, United States

  • Princess Alexandra Hospital ( Site 0253)

    Brisbane, Queensland, 4102, Australia

  • Princess Margaret Cancer Centre ( Site 0033)

    Toronto, Ontario, M5G 2M9, Canada

  • Rabin Medical Center ( Site 0043)

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus-Oncology Division ( Site 0042)

    Haifa, 3109601, Israel

  • Seattle Cancer Care Alliance ( Site 0010)

    Seattle, Washington, 98109, United States

  • Severance Hospital Yonsei University Health System ( Site 0300)

    Seoul, 03722, South Korea

  • Shanghai Chest Hospital-Oncology department ( Site 0801)

    Shanghai, Shanghai Municipality, 200030, China

  • Sourasky Medical Center ( Site 0041)

    Tel Aviv, 6423906, Israel

  • South Texas Accelerated Research Therapeutics, LLC (START) ( Site 0001)

    San Antonio, Texas, 78229, United States

  • The First Hospital of Jilin University ( Site 0803)

    Changchun, Jilin, 130021, China

  • The Oncology Centre ( Site 0212)

    Durban, KwaZulu-Natal, 4091, South Africa

  • The Ottawa Hospital ( Site 0031)

    Ottawa, Ontario, K1H 8L6, Canada

  • University General Hospital of Heraklion ( Site 0110)

    Heraklion, Irakleio, 711 10, Greece

  • University of California at San Francisco ( Site 0004)

    San Francisco, California, 94158, United States

  • Uniwersyteckie Centrum Kliniczne ( Site 0151)

    Gdansk, Pomeranian Voivodeship, 80-214, Poland

  • Utah Cancer Specialists ( Site 0011)

    Salt Lake City, Utah, 84106, United States

  • Washington University ( Site 0003)

    St Louis, Missouri, 63110, United States

  • West China Hospital of Sichuan University ( Site 0804)

    Chengdu, Sichuan, 610041, China

  • Wits Clinical Research ( Site 0213)

    Johannesburg, Gauteng, 2193, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.